Latest news with #heart failure
Daily Mail
20 hours ago
- Health
- Daily Mail
Autopsy for college football player who passed away suddenly at 18 reveals stunning cause of death
The cause of death for a University of Cincinnati freshman offensive lineman who passed away in April at his residence in Ohio has been revealed. Jeremiah Kelly - who was set to play his first season of college football for the Cincinnati Bearcats this fall - died from cardiac hypertrophy, according to documents obtained by ESPN. Cardiac hypertrophy is a disease which enlarges the heart muscle, which sometimes leads to heart failure or sudden cardiac arrest. Kelly's mother, Chiniqua Kelly, told the outlet that her son wore a heart monitor during workouts and that he'd been relaxing at his residence the day before his passing. She added that Jeremiah was her 'healthiest' child and he did not have any issues before his death. 'The Cincinnati football program and athletics department continue to mourn Jeremiah's passing,' a Cincinnati spokesperson said to ESPN. 'He is deeply missed by all of us.' The team spokesperson also said that Kelly passed a physical examination mandated by the NCAA before he participated in team activities. Kelly enrolled at Cincinnati early and was on campus for the team's spring practices to prepare for the upcoming season. 'The Bearcats football family is heartbroken by the sudden loss of this outstanding young man,' Cincinnati head coach Scott Satterfield said in April. 'In the short time Jeremiah has spent with our team, he has made a real impact, both on the field and in our locker room. 'My prayers are with the Kelly family and those who had the pleasure of knowing Jeremiah.' 247Sports rated Kelly as a three-star recruit to the school as a part of their Class of 2025. Cincinnati's recruiting class was ranked 14th out of 16 in the Big XII and 61st in the nation. Kelly - a native of Avon, Ohio - chose Cincinnati over an offer from the University of Akron. In high school, Kelly helped lead his team to a perfect 16-0 record and a state championship in his senior year.
Medscape
5 days ago
- Health
- Medscape
CMS Okays Coverage of Tricuspid TEER, With Caveats
The recent decision by the US Centers for Medicare and Medicaid Services (CMS) to cover tricuspid transcatheter edge-to-edge repair (T-TEER) could help change the model through which physicians think about right-side heart failure, according to one of the clinicians who worked on the trials of the procedure. On July 2, CMS agreed to cover T-TEER for the treatment of tricuspid regurgitation but only through the coverage with evidence development process, which requires procedures to be performed as part of a CMS-approved study. Some comments solicited during the decision process raised concerns T-TEER has not shown clinically meaningful benefit and that the TRILUMINATE pivotal trial did not show a decrease in mortality, tricuspid valve surgeries, or overall hospitalizations compared to medical therapy. 'While we agree that there are evidence gaps that still need to be addressed regarding T-TEER, we believe the evidence overall, while insufficient, is promising enough to allow coverage with evidence development,' CMS said in announcing its decision. The study criteria — all-cause mortality and hospitalizations through a minimum of 24 months — 'strike the appropriate balance between evidence generation and patient access,' the agency said. The patient must have symptomatic tricuspid regurgitation despite optimal medical therapy and be under the care of a heart team that includes a cardiac surgeon, an interventional cardiologist, a heart failure specialist, and an interventional echocardiographer. Shamir Mehta, MD, cardiologist at McMaster University in Hamilton, Ontario, Canada, and an investigator on TRILUMINATE, said the trial provided evidence of benefit. 'The trial showed improvements in quality of life, and that's an important outcome from the patients' perspective,' Mehta said. And TRILUMINATE did see a reduction in heart failure hospitalization at 2 years, he noted. 'Maybe over the longer term, we begin to see that correlating with a reduction in tricuspid regurgitation,' he said. Mehta acknowledged some of the criticisms of TRILUMINATE were valid but said the main issue was some of the assumptions underlying the trial turned out not to be correct. Prior to TRILUMINATE, right heart failure and tricuspid regurgitation were understudied, so the study and the subsequent TRISCEND II trial were designed using the same paradigm for reduction in events that are used for left-sided heart failure, he said. 'We made an assumption that the same outcomes that we observed in mitral regurgitation would also apply to patients with right heart failure,' he said. 'Maybe, the outcomes that we should be looking at with right-sided heart failure should be different.' Patients with left-sided heart failure tend to present with pulmonary edema and require hospitalisation for acute heart failure. While those with right-sided heart failure accumulate fluid in the periphery and are often not admitted to hospital but treated in the clinic with diuretics and develop and are admitted for other complications such as renal failure. 'There are two types of heart failure, and they can present in very different ways,' Mehta said. The trials that will be conducted under the CED process should help to clarify those differences, and lead to a better understanding of when T-TEER is the right choice for a patient. 'This is an evolving area and we're learning more as we have more randomized trials,' he said. Mehta is an investigator on the TRILUMINATE and CLASP TR trials.
Zawya
6 days ago
- Health
- Zawya
KFSHRC performs world's first robotic-assisted BiVAD Implantation
A minimally invasive robotic surgery offers a life-saving option for high-risk patients who cannot undergo transplants or traditional open-heart procedures King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world's first implantation of two artificial pumps for biventricular support (BiVAD-HMIII) using robotic technology on a patient with advanced heart failure. This groundbreaking procedure opens new horizons in circulatory support techniques for patients with complex cardiac conditions and marks a medical achievement that culminated in the patient's recovery within a short period following the surgery. The procedure represents a major advancement in the treatment of bilateral heart failure, which was traditionally performed through full sternotomy, an approach associated with higher surgical risks and prolonged recovery. However, the cardiac surgery team at KFSHRC, led by Prof. Feras Khaliel, successfully performed the operation through small incisions using remotely controlled high-precision robotic arms, resulting in reduced blood loss, lower risk of infection, and faster patient recovery. The 61-year-old patient was admitted after spending over two months bedridden, suffering from end-stage heart failure unresponsive to medical therapy, in addition to multiple chronic conditions including diabetes, stroke, and renal impairment. After a comprehensive clinical evaluation, the patient was deemed ineligible for a heart transplant, making robotic implantation of the artificial pumps a vital and unique solution suited to his health status. This milestone reflects the integration of expertise across multiple departments at KFSHRC including cardiac surgery, cardiology, anesthesia, critical care, biomedical engineering, and advanced life support. The procedure was meticulously planned and benefited from 3D imaging technologies, real-time surgical navigation, and innovative solutions for safely securing the mechanical assist devices. KFSHRC aims to publish the results of this procedure in peer-reviewed medical journals and present them at global cardiology conferences to promote knowledge exchange and establish innovative partnerships with leading international centers in robotic care and advanced heart failure management. This achievement adds to KFSHRC's track record in robotic surgery which includes the world's first fully robotic heart transplant and the World's First Robotic-Assisted Artificial Heart Pump Implantation. These milestones serve as evidence of its leadership in adopting cutting-edge cardiac technologies and managing critical conditions with the highest standards of precision and safety, further reinforcing its position as a leading academic medical center both regionally and globally. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world's top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best 250 hospitals and included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Japan Times
14-07-2025
- Health
- Japan Times
Japan's Emperor Emeritus admitted to hospital to begin new heart treatment
Emperor Emeritus Akihito was admitted to the University of Tokyo Hospital on Monday afternoon to begin taking a new oral treatment for his heart. The 91-year-old former emperor will take the treatment to alleviate burdens on his heart, in addition to his ongoing medication. Dosage for the new treatment will be decided after he undergoes an electrocardiogram. In July 2022, the emperor emeritus was diagnosed with heart failure on the right side of his heart, caused by tricuspid valve insufficiency. He was admitted to the university hospital in May for a heart examination and diagnosed with asymptomatic myocardial ischemia. According to his aides, the emperor emeritus has carried out low-strain exercises and walks to maintain his health since the May hospitalization. He also began taking medication to improve coronary artery blood flow. As these efforts did not lead to improvements, a team of doctors concluded that the additional oral treatment was necessary. It is yet to be determined how long the emperor emeritus will stay at the hospital. He may be discharged relatively swiftly once the dosage is decided based on his heart and overall condition.
